Exondys 51 accounted for the majority of Sarepta's total revenues of $701 million last year, with support from its two other approved exon-skipping DMD therapies, Vyondys 53 and Amondys 45. Image ...

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four clinical ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...

Consumer groups ask FTC to block Novo Holdings-Catalent deal Sanofi-owned biotech company Genzyme has sued rival Sarepta Therapeutics in Delaware federal court for allegedly infringing two patents ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital reiterated a Buy rating ...

https://www.tipranks.com/news/the-fly/ptc-therapeutics-price-target-raised-to-71-from-47-at-ubs Arrowhead (ARWR) announced a global licensing and collaboration ...